High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Gene expression profiling reclassifies aggressive non-Hodgkin lymphomas (aNHL).
• Aberrant c-Myc activity, often from IG-MYC translocations in Burkitt lymphoma (BL), impacts prognosis in other aNHL.
• MYC aberrations have a negative prognostic impact beyond BL.

Purpose of the Study:

• Investigate the functional role of aberrant c-Myc activity in various aNHL.
• Determine if c-Myc's role is independent of MYC translocations.
• Develop a tool to measure c-Myc activity in lymphomas.

Main Methods:

• Combined microarray analysis of human germinal center (GC) B cells transfected with c-Myc.
• Analysis of 220 aggressive non-Hodgkin lymphoma (aNHL) cases.
• Development of a "c-Myc index" to quantify c-Myc responsive gene expression.

Main Results:

• The "c-Myc index" was very high in molecular Burkitt lymphoma (mBL) and also high in other aNHL.
• Aberrant c-Myc expression in GC B cells triggers a tumor-like gene expression pattern.
• The "c-Myc index" is a negative prognostic marker, independent of established risk factors and MYC translocations.

Conclusions:

• Aberrant c-Myc activity plays a significant functional role in diverse aggressive non-Hodgkin lymphomas (aNHL).
• The "c-Myc index" serves as a novel, independent negative prognostic marker in aNHL.
• Findings suggest potential treatment modifications for high-risk patients based on c-Myc activity.